Investigate the mechanisms of Chinese medicine Fuzhengkangai towards EGFR mutation-positive lung adenocarcinomas by network pharmacology

Nuclear translocation of IGF1R by intracellular amphiregulin contributes to the resistance of lung tumour cells to EGFR-TKI

(2018) Marie Guerard et al.   CANCER LETTERS

Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase

(2018) Jiang-Kai Dong et al.   Theranostics

Exploring the pharmacological mechanism of Yanghe Decoction on HER2-positive breast cancer by a network pharmacology approach

(2017) Liuting Zeng et al.   JOURNAL OF ETHNOPHARMACOLOGY

Polyphyllin VII increases sensitivity to gefitinib by modulating the elevation of P21 in acquired gefitinib resistant non-small cell lung cancer

(2017) Honggang Wang et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

Identification of the active compounds and significant pathways of yinchenhao decoction based on network pharmacology

(2017) Jihan Huang et al.   Molecular Medicine Reports

TCM-Mesh: The database and analytical system for network pharmacology analysis for TCM preparations

(2017) Run-zhi Zhang et al.   Scientific Reports

Cancer statistics in China, 2015

(2016) Wanqing Chen et al.   CA-A CANCER JOURNAL FOR CLINICIANS

PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation

(2016) D.-W. Wu et al.   CLINICAL CANCER RESEARCH

A novel systems pharmacology platform to dissect action mechanisms of traditional Chinese medicines for bovine viral diarrhea disease

(2016) Chunli Zheng et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Systematic understanding the mechanisms of vitiligo pathogenesis and its treatment by Qubaibabuqi formula

(2016) Tianli Pei et al.   JOURNAL OF ETHNOPHARMACOLOGY

Induction of C/EBP homologous protein-mediated apoptosis and autophagy by licochalcone A in non-small cell lung cancer cells

(2016) Zheng-Hai Tang et al.   Scientific Reports

Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: Comparison of two chemotherapy regimens (IFCT-0702: A randomized phase 3 final results study)

(2015) Denis Moro-Sibilot et al.   LUNG CANCER

Effect of gefitinib plus Chinese herbal medicine (CHM) in patients with advanced non-small-cell lung cancer: A retrospective case–control study

(2014) Xiao-Bing Yang et al.   COMPLEMENTARY THERAPIES IN MEDICINE

Monoamine oxidase A suppresses hepatocellular carcinoma metastasis by inhibiting the adrenergic system and its transactivation of EGFR signaling

(2014) Jun Li et al.   JOURNAL OF HEPATOLOGY

Beta-2 Adrenergic Receptor (ADRB2) Gene Polymorphisms and the Risk of Asthma: A Meta-Analysis of Case-Control Studies

(2014) Si-Qiao Liang et al.   PLoS One

TCMSP: a database of systems pharmacology for drug discovery from herbal medicines

(2014) Jinlong Ru et al.   Journal of Cheminformatics

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

Systems pharmacology uncovers Janus functions of botanical drugs: activation of host defense system and inhibition of influenza virus replication

(2012) Xia Wang et al.   Integrative Biology

Network pharmacology-based prediction of the active ingredients and potential targets of Chinese herbal Radix Curcumae formula for application to cardiovascular disease

(2012) Weiyang Tao et al.   JOURNAL OF ETHNOPHARMACOLOGY

Low incidence of hepatitis B e antigen seroconversion in patients treated with oral nucleos(t)ides in routine practice

(2012) Brian Lin et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

(2012) Zhenfeng Zhang et al.   NATURE GENETICS

clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters

(2012) Guangchuang Yu et al.   OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1

(2012) K. Ohashi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation

(2012) Ken Takezawa et al.   Cancer Discovery

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

(2011) Caicun Zhou et al.   LANCET ONCOLOGY

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

Cytoscape 2.8: new features for data integration and network visualization

(2010) M. E. Smoot et al.   BIOINFORMATICS

Licorice and Licochalcone-A Induce Autophagy in LNCaP Prostate Cancer Cells by Suppression of Bcl-2 Expression and the mTOR Pathway

(2009) Yi-Te Yo et al.   JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY

Discovery of 3-(1H-Indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione (AEB071), a Potent and Selective Inhibitor of Protein Kinase C Isotypes

(2009) Jürgen Wagner et al.   JOURNAL OF MEDICINAL CHEMISTRY

Effect of β2-Adrenergic Receptor Polymorphism in Asthma Control of Patients Receiving Combination Treatment

(2009) Seung-Hyun Kim et al.   YONSEI MEDICAL JOURNAL